IDH2 and acute myeloid leukemia: In a phase 2 trial on enasidenib and azacitidine combination in patients with IDH2 mutated AML who are not eligible for intensive treatment, the association of enasidenib, azacytidine, and venetoclax was tested in 11 patients (4 with newly diagnosed AML and 7 with R/R AML) with a CR rate of 86% [107].